Altimmune Showcases Pemvidutide at European Diabetes Conference
Altimmune, Inc. (Nasdaq: ALT), a leading clinical-stage biopharmaceutical company, has announced an exciting development regarding its innovative treatment, pemvidutide. The company is preparing to present significant findings from its Phase 2 clinical study at the esteemed 60th Annual Meeting of the European Association for the Study of Diabetes. This important event will be held in Madrid, where experts will convene to discuss the latest advancements in diabetes treatment and research.
Importance of the Clinical Data
The clinical data being presented highlights the MRI-based body composition sub-study of pemvidutide in individuals facing challenges with overweight and obesity. Pemvidutide is a promising investigational drug that functions as a dual receptor agonist for GLP-1 and glucagon. This treatment not only aims to promote weight loss but also seeks to tackle metabolic dysfunction associated with steatohepatitis.
Details of the Presentation
Here are the details of the presentation:
- Title: Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study.
- Presenter: Sarah Browne, M.D., Vice President of Clinical Development at Altimmune.
- Date/Time: September 10, 2024, at 1:45 pm CEST.
Understanding Pemvidutide
Pemvidutide marks a significant advancement in obesity treatment. By harnessing the synergistic effects of GLP-1 and glucagon, the drug aims to replicate the benefits of healthy eating and regular physical activity. The GLP-1 component helps to reduce appetite, while glucagon is known to enhance energy expenditure. In addition to supporting weight loss, glucagon plays an essential role in improving liver fat metabolism, leading to beneficial outcomes such as reduced liver fat and enhanced blood lipid profiles.
Clinical Trials and Progress
So far, clinical trials have shown promising results for once-weekly administration of pemvidutide, demonstrating significant weight loss along with notable reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. Recognizing its potential, the U.S. FDA has granted Fast Track designation to pemvidutide, highlighting the urgency of its development for treating MASH. Currently, pemvidutide is wrapping up the MOMENTUM Phase 2 obesity trial and is actively being investigated in the ongoing IMPACT Phase 2b MASH trial.
About Altimmune
Altimmune is dedicated to developing next-generation peptide-based therapeutics aimed at addressing significant health challenges. Their commitment to advancing pemvidutide as a treatment for obesity and MASH showcases their focus on innovation in healthcare. For those who wish to stay informed about Altimmune's progress and developments, the company provides resources and updates through their official website.
Contact Information for Altimmune
If you have any questions or need further information, you can contact Altimmune using the following details:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
Email: ir@altimmune.com
Frequently Asked Questions
What is the focus of Altimmune's presented data?
The data focuses on pemvidutide's effects on preserving lean body mass during weight loss for individuals with overweight and obesity.
What is pemvidutide?
Pemvidutide is an investigational peptide-based GLP-1/glucagon dual receptor agonist aimed at treating obesity and liver-related metabolic issues.
What are the benefits of GLP-1 and glucagon receptor activation?
Activation of these receptors is thought to imitate the positive effects of diet and exercise, leading to reduced appetite and boosted energy expenditure.
Has pemvidutide received any FDA recognition?
Yes, the U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of metabolic dysfunction-related liver disease.
Who presented the pemvidutide data at the conference?
The data will be presented by Dr. Sarah Browne, Vice President of Clinical Development at Altimmune.
